US Patent

US9493582 — Alkylated cyclodextrin compositions and processes for preparing and using the same

Formulation · Assigned to Cydex Pharmaceuticals Inc · Expires 2033-02-27 · 7y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects low-chloride alkylated cyclodextrin compositions and processes for preparing and using them.

USPTO Abstract

The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.

Drugs covered by this patent

Kyprolis (carfilzomib) · Amgen
fosphenytoin-sodium (FOSPHENYTOIN SODIUM)
melphalan-hydrochloride (MELPHALAN HYDROCHLORIDE)
Tegretol (carbamazepine) · Novartis AG (originally Geigy)
posaconazole (POSACONAZOLE)
delafloxacin-meglumine (DELAFLOXACIN MEGLUMINE)

Patent Metadata

Patent number: US9493582
Jurisdiction: US
Classification: Formulation
Expires: 2033-02-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Cydex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.